Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

BACKGROUND: Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs display primary or acquired TKI resistance. TKI resistance can be either caused b...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Commun Signal
Main Authors: Halbach, Sebastian, Hu, Zehan, Gretzmeier, Christine, Ellermann, Julia, Wöhrle, Franziska U., Dengjel, Jörn, Brummer, Tilman
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Short Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4765141/
https://ncbi.nlm.nih.gov/pubmed/26912052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12964-016-0129-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares